Health Condition 1: null- Cancer patients with hematological malignancies.
Conditions
Interventions
None listed
Sponsors
Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Patients between age 1 and 60 years presenting to TMH, Parel with de novo hematological malignancy (newly diagnosed and not having received chemotherapy outside) and who will be treated with curative intent.
Exclusion criteria
Exclusion criteria: 1) Those will myelodysplastric syndromes. 2) Those with secondary leukemias. 3) Those who have received prior chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The study is intended to arrive at a bleeding risk index for Indian patients with hematological malignancies undergoing chemotherapy.Timepoint: First itme point will be when the patient is enrolled into study. Second time point is after completion of first phase of chemotherapy. Third time point will be after completion of second phase of chemotherapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Revisit the prophylactic thresholds for various co morbidities, namely: febrile neutropenia, fungal pneumonia, oral mucositis in adults and sepsis. 2) % of outpatients with stable thrombocytopenia and platelet count above 20k/µl, who were given platelets. 3)% of inpatients with stable thrombocytopenia and platelet count above 10k/µl, who were given platelets. 4) To correlate the grade of bleeding (WHO grades) and the platelet counts at which they occurred. Timepoint: 1) During first phase of chemotherapy 2) During 2nd phase of chemotherapy | — |
Countries
India
Contacts
Public ContactDr Parayacade Joseph Sanal
Tata Memorial Hospital
Outcome results
None listed